Ibex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision Diagnostics

Top experts Dr. Ruth March and Dr. Paolo Tarantino named as members, with additional appointments to follow

TEL AVIV, Israel--(BUSINESS WIRE)--Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced the appointment of Ruth March, PhD and Paolo Tarantino, MD, PhD to its newly established Biopharma Advisory Board. Dr. Tarantino and Dr. March are the first members of the Advisory Board, with additional experts expected to join in the coming months.

The formation of the Advisory Board reflects Ibex’s strategic expansion into biopharma and its commitment to partnering with industry leaders to advance AI-driven biomarker development and precision diagnostics. As oncology rapidly evolves toward antibody-drug conjugates (ADCs) and other targeted therapies, the need for precise, reproducible biomarker quantification and scoring has become increasingly critical. The Board will provide strategic and scientific guidance as the company expands its Biopharma Services offering to support partners across the full lifecycle, from early biomarker and AI-powered companion diagnostics (CDx) development through clinical validation and global deployment via Ibex’s established clinical market.

"The complexity of cancer biology today requires more than just research prototypes; it demands practical, rigorous tools that can transition seamlessly from the lab to the clinic," said Joseph Mossel, Co-Founder and President of Ibex Medical Analytics. "We are grateful to have Dr. Tarantino and Dr. March join us. Their deep expertise ensures Ibex remains grounded in the practical needs of pharmaceutical development. By leveraging our established clinical network, we are able to reduce risk in clinical development and expand market reach for our partners, moving beyond early-stage AI concepts toward reliable, clinical-grade deployment."

Ruth March, PhD, OBE, FMedSci, FRSB, joins the board following a transformative tenure as Senior Vice President of Precision Medicine and Biosamples at AstraZeneca. Dr. March is a pioneer in the field, having led the approval of more than 70 companion diagnostics for six launched drugs across major global markets. Her career is marked by industry firsts, including the world’s first approval of circulating tumor DNA (ctDNA) to guide therapy and the development of digital pathology biomarkers as companion diagnostics. An expert in population genomics, she also initiated AstraZeneca’s genomics initiatives, utilizing machine learning to analyze millions of genomes. Her contributions to the life sciences were recognized with an OBE for her leadership during the COVID-19 pandemic.

"In my role at AstraZeneca, I saw firsthand the transformative potential of AI to accelerate diagnostics and advance precision medicine," said Dr. March. "I worked with Ibex for many years and now feel privileged to continue to support them in an advisory role. Their technology has the potential to deliver precise, reproducible biomarker quantification and scoring, combined with a proven global clinical footprint that enables rapid translation from development to real-world use."

Paolo Tarantino, MD, PhD, is a distinguished breast medical oncologist and clinical researcher. He currently serves as a Research and Clinical Fellow at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Tarantino’s work is at the forefront of the ADC revolution, specifically focusing on mechanisms of action and the development of novel predictive biomarkers to increase treatment precision. A prolific academic, he has published over 100 scientific articles and is a key contributor to numerous clinical trials and preclinical investigations aimed at optimizing outcomes for breast cancer patients.

Ibex’s expanded Biopharma Services offering builds on a proven pharma partnership model, exemplified by the development of Ibex Breast HER2, which progressed from algorithm development through clinical validation, regulatory certification, and real-world deployment using Ibex’s end-to-end capabilities. By combining robust quantification and customizable scoring approaches with a regulatory-grade platform and global clinical deployment footprint, Ibex enables pharmaceutical partners to develop, validate, and scale AI-driven diagnostics with confidence, from early development through commercialization.

About Ibex Medical Analytics

Ibex is a global leader in clinical-grade AI for pathology, with deployed solutions in over 50 health systems and partnerships spanning life-science companies, reference laboratories, and digital pathology vendors. Ibex’s platform supports biomarker discovery, clinical trial efficiency, and CDx-ready evidence generation, backed by an ISO 13485-compliant QMS.

The Ibex platform includes solutions that are CE-IVD certified and registered with the UK MHRA, TGA in Australia, ANVISA in Brazil and AMAR in Israel. It includes a solution that is FDA cleared and others that are Research Use Only (RUO) in the United States.